Core Viewpoint - Qingdao Sanbaisuo Health Technology Co., Ltd. has approved the use of up to RMB 500 million of temporarily idle raised funds for cash management, ensuring that it does not affect the normal investment plans and safety of the raised funds [1][3]. Group 1: Cash Management Approval - The company held its 8th meeting of the 2nd Board of Directors and the 2nd Supervisory Board on April 25, 2025, where it approved the proposal for cash management using idle raised funds [1]. - The cash management period is set for 12 months from the date of approval, with individual investment products not exceeding 12 months [1]. Group 2: Investment Products Overview - The company has recently invested in various financial products using idle raised funds, including structured deposits and wealth management products from banks [1][2]. - Specific investments include: - RMB 4 million in a structured deposit with a 1.95% expected annual return [1]. - RMB 6 million in a 29-day structured deposit with an expected return of 1.85% [1]. - RMB 84 million in a structured deposit with a 2.47% expected return [1][2]. Group 3: Impact on Operations - The use of idle raised funds for cash management is aimed at optimizing the efficiency of fund usage without affecting the normal operations of the company's main business [3]. - The cash management strategy is expected to generate additional investment income, enhancing the overall performance of the company and providing better returns for shareholders [3]. Group 4: Compliance and Risk Management - The company emphasizes that the cash management activities comply with relevant regulations and internal control systems, ensuring that there is no change in the intended use of the raised funds [2][3]. - The company has established measures to monitor and control investment risks associated with cash management [3].